GILD is hoping that SOF+RBV will fare better in GT1b than the 50% that you quote.
PEG costs money, and that money does not go to GILD. This is a business decision that assumes that clinically the regimen will show enough efficacy to be competitive with IFN-based triples in a GT1b (easy to cure) dominant price-constrained market.
Market Data 
Markets 
AI
